Letolizumab - Bristol-Myers Squibb

Drug Profile

Letolizumab - Bristol-Myers Squibb

Alternative Names: BMS-986004; BMS2h-572-633-CT-L2

Latest Information Update: 06 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bristol-Myers Squibb
  • Class Anti-inflammatories; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Idiopathic thrombocytopenic purpura

Most Recent Events

  • 06 Aug 2018 Bristol Myers Squibb has patent pending for antibody polypeptides that antagonise CD40 ligand in world (201305606 A1)
  • 30 Jul 2018 Bristol-Myers Squibb plans a phase I/II trial for Graft-versus-host-disease (Prevention) in USA , (NCT03605927)
  • 15 Feb 2018 Bristol-Myers Squibb completes a phase I/II trial in Immune thrombocytopenic purpura in Russia, Canada, Australia, USA, Georgia, Moldova, Poland and the United Kingdom (IV) (NCT02273960)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top